CF33-hNIS-antiPDL1. *moves mouse to x button to close tab* “But wait!” your writer screams from the page, “I promise it's…
Cancer treatment is slowly shifting away from the standard chemo and radiation and more towards immunotherapy as an alternative treatment.…
Australian biotech company Immutep (ASX: IMM, NASDAQ: IMMP) has delivered impressive Phase I clinical trial results for its TACTI-mel trial…